Targets › GPNMB
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2028.
Could be a melanogenic enzyme. (UniProt, Q14956)
Open in Phaseline: the race on GPNMB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Canadian Cancer Trials Group | GCAR1 anti-GPNMB CAR-T cell therapy | GPNMB | Phase 1 | Alveolar Soft Part Sarcoma | Dec 2028 |
Alveolar Soft Part Sarcoma (1)
mixed (1)
Canadian Cancer Trials Group (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.